U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070622) titled 'Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)' on July 08.
Brief Summary: On the basis of our previous study, this project further explored whether patients with effective neoadjuvant chemotherapy can obtain a higher organ preservation rate after total neoadjuvant therapy. This study was designed to enroll patients with low and intermediate-risk rectal cancer. After 2 cycles of XELOX chemotherapy, patients with effective chemotherapy as judged by high-definition MRI of the rectum (the long diameter of the tumor was shortened by >=30% compared with that before treatment) were randomly divided ...